Lv1
45 积分 2021-01-18 加入
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes
20天前
已完结
Unexpectedly High Incidence of Immune-Related Adverse Events in Gastric Cancer Patients Who Received Conversion Surgery After Nivolumab-Including Chemotherapy
1个月前
已关闭
Abstract 3228: Characterization of multi-organ system involvement of immune-related adverse events after anti-PD-(L)1 monotherapies: A pooled analysis of clinical trial data submitted to FDA
1个月前
已完结
A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single-institutional experience
1个月前
已完结
A first-line regimen combining Bruton's tyrosine kinase and programmed cell death protein-1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma
1个月前
已完结
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study
2个月前
已完结
First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial
4个月前
已完结
Continued value of adjuvant anthracyclines as treatment for early breast cancer
4个月前
已关闭
Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial
4个月前
已完结
Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel
4个月前
已完结
皖公网安备34019202002308
